Immune checkpoint inhibitor nivolumab induces durable response in microsatellite instability-high and DNA damage repair-deficient metastatic castration-resistant prostate cancer
机构：[1]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Prostate cancer is the second most common malignancy in
men worldwide, and its incidence in China continues to rise
[1]. Despite advances in androgen deprivation therapy (ADT)
and androgen receptor (AR) pathway inhibitors, many
patients eventually progress to metastatic castration-resistant
prostate cancer (mCRPC). Based on molecular features,
mCRPC can be classified into AR-driven, DNA damage
repair (DDR)-deficient, microsatellite instability-high (MSIH)/mismatch repair-deficient (dMMR), and neuroendocrinelike subtypes, each with distinct biological characteristics and
therapeutic implications [2]. Although DDR and MMR
deficiencies are relatively uncommon, they offer actionable
therapeutic opportunities. MSI-H/dMMR tumours are
associated with a high tumour mutational burden (TMB) and
abundant neoantigen expression, providing a strong rationale
for immune checkpoint blockade. MSI-H/dMMR status has
been used to guide programmed death 1 (PD-1) inhibitor
therapy in various malignancies, e.g., in colorectal cancer,
providing a rationale for its application in selected patients
with mCRPC [3].
基金：
the National Natural Science
Foundation of China (grant numbers 82370775 and
82170784) and the National Key Research and Development Program of China (2022YFC3602902, 2022YFC3602901).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|2 区医学
小类|2 区泌尿学与肾脏学
最新[2025]版：
大类|2 区医学
小类|2 区泌尿学与肾脏学
第一作者：
第一作者机构：[1]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
